Stifel lowered the firm’s price target on SLB (SLB) to $60 from $62 and keeps a Buy rating on the shares. Though international growth rates are slowing, the firm says Q3 results, Q4 guidance, and the 2025 outlook support its belief that the risk/reward in the shares remains favorable and that SLB is well positioned to deliver solid growth and robust free cash flow over the next few years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLB:
- SLB price target lowered to $61 from $63 at Barclays
- SLB price target lowered to $62 from $74 at Evercore ISI
- Netflix reports Q3 beat, CVS CEO Lynch steps down: Morning Buzz
- SLB Earnings: SLB’s Q3 Earnings Rise amid Cautious Market Conditions
- Morning Movers: CVS Health sinks following CEO change, weak guidance